Russell Investments Group
CMPX icon

Russell Investments Group’s Compass Therapeutics CMPX Stock Holding History

Russell Investments Group’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$57.7K Sell
10,900
-658
-6% -$3.8K ﹤0.01% 3278
2025
Q4 		$62.1K Buy
11,558
+3,773
+48% +$17.4K ﹤0.01% 3217
2025
Q3 		$27.2K Buy
7,785
+7,592
+3,934% +$24K ﹤0.01% 3499
2025
Q2 		$502 Hold
193
– – ﹤0.01% 3744
2025
Q1 		$367 Hold
193
– – ﹤0.01% 3699
2024
Q4 		$280 Buy
+193
New +$321 ﹤0.01% 3645

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Russell Investments Group's CMPX Position: Q1 2026 in Review

Russell Investments Group reduced its Compass Therapeutics (CMPX) stake by 5.7% in Q1 2026, selling an estimated $3.8K and leaving 10,900 shares worth $57.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3278.

Russell Investments Group first reported a position in CMPX in Q4 2024 and has held it in 6 quarters since. The position peaked at $62.1K in Q4 2025. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • Russell Investments Group held 10,900 shares of Compass Therapeutics worth $57.7K as of Q1 2026.
  • Russell Investments Group sold 658 Compass Therapeutics shares in Q1 2026, an estimated $3.8K.
  • Compass Therapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q1 2026, its #3278 holding.
  • Russell Investments Group first reported a position in Compass Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Russell Investments Group's Compass Therapeutics position peaked at $62.1K in Q4 2025.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on Russell Investments Group's 13F filing for Q1 2026, filed 8 May 2026.